恶性血液病患者中侵袭性真菌病的二级预防

发布时间：2018-06-17 02:15

本文选题：侵袭性真菌病 + 恶性血液病　；参考：《中国实验血液学杂志》2015年02期

【摘要】：侵袭性真菌病在恶性血液病患者中发病率及死亡率均很高,有真菌感染病史的患者在进一步的化疗或造血干细胞移植中真菌感染复燃率高、预后差。真菌的二级预防可有效地预防真菌感染复燃。给予有效的二级预防,既往侵袭性真菌感染病史不影响化疗继续进行,也不再是异基因造血干细胞移植的绝对禁忌症。已经证明广谱抗真菌药物如伏立康唑、伊曲康唑、两性霉素B、卡泊芬净作为二级预防药物取得了很好的疗效,但在粒细胞缺乏和免疫抑制状态下预防真菌感染复燃仍然面临巨大的挑战。本文就恶性血液病患者中二级抗真菌预防的现状作一综述。
[Abstract]:The incidence and mortality of invasive mycosis in patients with malignant hematologic diseases were very high. The recurrence rate of fungal infection in patients with history of fungal infection was high and the prognosis was poor during further chemotherapy or hematopoietic stem cell transplantation. The secondary prevention of fungi can effectively prevent the recurrence of fungal infection. With effective secondary prevention, the history of invasive fungal infection does not affect the continuation of chemotherapy, nor is it an absolute taboo for allogeneic hematopoietic stem cell transplantation. It has been proved that broad-spectrum antifungal drugs such as voriconazole, itraconazole, amphotericin B, and carpofen have good curative effect as secondary prophylaxis. However, the challenge of preventing the recurrence of fungal infection in granulocyte deficiency and immunosuppressive state remains enormous. This article reviews the current status of secondary antifungal prevention in patients with malignant hematologic diseases.
【作者单位】：中国人民解放军总医院血液科;解放军第309医院血液科;
【基金】：国家自然科学基金(81470010) 首都市民健康项目培育(Z111107067311070) 解放军301医院技术创新苗圃基金(13KMM01)
【分类号】：R733;R519

【参考文献】